持续推动医疗影像领域变革。 本文为IPO早知道原创 作者｜ Stone Jin 微信公众号｜ipozaozhidao 据 IPO早知道消息， 数坤科技 日前在 CMEF 上亮相了升级后的 "数坤坤" 多模态医疗健康大模型 （以下简称"数坤坤"大模型） 。 依托这一前沿大模型，数坤科技推出了数字人体 4.0技术平台以及平台之上被"数坤坤"大模型全面赋 能升级后的数智影像、数智超声、数智医院、数智基层解决方案，和一系列加载了"数坤坤"能力的AI 原生硬件。 数坤科技创始人、董事长毛新生 表示， 数字人体 4.0将带动医疗健康产业升级进入新阶段，希望通 过数字化的人体，让所有的医生在为病人服务时能拥有跟今天完全不同的智能化手段。数坤在大模型 本身以及模型应用方面，都走在全世界的前列。 作为医疗垂类大模型， "数坤坤"已经可以识别出CT、MR、DR、X-ray、钼靶以及超声等模态的影 像数据，深刻理解患者的生化检查、诊断报告、既往病史和现病史等文本信息。同时，在学习了公域 这种创新模式相当于为医生配备了处理繁琐工作的 "智能助手"，显著提升诊疗效率与质量；同时为 患者提供24小时在线的"专属医生"，实现个性化的健康管 ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [2][11]. Core Insights - New technology platforms are increasingly favored by multinational corporations (MNCs), leading to earlier collaboration opportunities. A notable example is the global strategic partnership between Heptares Therapeutics and AstraZeneca, which includes a $105 million equity investment [3]. - The weight loss market is seeing multiple business developments (BD) materialize, with significant sales growth reported by Novo Nordisk and Eli Lilly. Novo Nordisk's core products generated approximately $27.94 billion in sales, while Eli Lilly's tirzepatide saw a 124% year-on-year increase in sales to $11.54 billion [5]. - Progress in universal CAR-T and solid tumor cell therapies is ongoing, with global CAR-T sales projected at approximately $4.53 billion in 2024. Chinese companies are also participating in this market, with three domestic CAR-T products approved for sale [6]. - The CRO (Contract Research Organization) environment may experience changes, with potential supply flexibility due to the easing of U.S. bioterrorism law concerns. This could enhance the competitiveness of Chinese CROs [7]. - The active pharmaceutical ingredient (API) sector is exploring new applications, particularly in the nicotine tobacco production sector, leveraging synthetic biology technologies [8]. - Major hospitals are launching specialized AI models, indicating a rising trend in the integration of AI in healthcare, with collaborations between tech companies and healthcare providers [10]. Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 0.88 percentage points over the past week, ranking 20th among 31 primary industry indices [20]. 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical sector's index has a current PE (TTM) of 30.95, which is below the five-year historical average of 32.98 [36]. 3. Recent Research Achievements - The research team has published several in-depth reports on various pharmaceutical sectors, highlighting trends such as the growth of blood products and the impact of policy support on inhalation drug industries [40]. 4. Important Industry Policies and News - Recent policy changes include the National Medical Products Administration's (NMPA) decision to abolish certain medical device standards to optimize the regulatory framework [42]. - Significant industry news includes the approval of several new drug applications and clinical trials by the NMPA, indicating a robust pipeline for pharmaceutical innovation [44][46].

Core Viewpoint - The article highlights the launch of "福棠·百川," the world's first pediatric large model developed by Baichuan Intelligence in collaboration with Beijing Children's Hospital and Xiaoerfang Health, which aims to provide personalized and evidence-based medical solutions for pediatric patients [1]. Group 1: Technological Breakthrough - "福棠·百川" is not just a medical knowledge base but a comprehensive pediatric knowledge system with strong clinical reasoning capabilities [3]. - The model is built on a vast medical database containing over one trillion tokens, including Chinese and English medical papers, guidelines, and textbooks [3]. - It integrates clinical experiences from over 300 renowned experts at Beijing Children's Hospital and high-quality anonymized medical records [3]. - The model is enhanced in five dimensions: evidence-based practice, reasoning, memory, dialogue, and multimodal capabilities [3]. - A self-built evidence-based medical knowledge base includes over 40,000 guidelines and expert consensus documents, 38 million research papers, and 170,000 drug instructions [3]. Group 2: Application Implementation - Two AI pediatric doctor applications have been launched based on the model, targeting different scenarios [5]. - The "福棠·百川" AI Pediatric Doctor Basic Version focuses on routine pediatric disease diagnosis, achieving diagnostic capabilities equivalent to attending physicians at Beijing Children's Hospital in respiratory and digestive fields [5]. - The "福棠·百川" AI Pediatric Doctor Expert Version is designed for multidisciplinary consultations and inpatient case analysis, with a 95% agreement rate with expert consultation results [5]. Group 3: National Layout - The model will be piloted in community hospitals in Haidian District and Economic Development Zone of Beijing, as well as over 150 county-level hospitals in Hebei Province, linking with the pediatric medical alliance in Beijing [6]. - The dual-doctor system, combining AI doctors with real doctors, aims to address the uneven distribution of quality pediatric medical resources and set a benchmark for the national hierarchical medical system [6]. - This initiative not only alleviates the shortage of pediatric doctors at the grassroots level but also fundamentally improves the quality of medical services, significantly contributing to the overall hierarchical medical system in China [6].

Group 1 - Company plans to invest 70 million yuan to acquire 0.70% equity in Shanghai United Imaging Intelligent Medical Technology Co., Ltd. (United Imaging Intelligent) [1] - After the investment, the total equity held in United Imaging Intelligent will be 0.9849% [1] - The controlling shareholder of the company, United Imaging Medical Group Co., Ltd., and Shanghai Lianhe Investment Co., Ltd. will also participate in the investment, acquiring 2.0000% and 1.7901% equity respectively [1] Group 2 - United Imaging Intelligent is a medical AI company providing integrated intelligent solutions across multiple scenarios and diseases, playing a crucial role in the AI strategy of United Imaging Group [2] - The company has launched over 100 medical AI products, excelling in clinical applications such as disease screening, early diagnosis, and treatment planning [2] - The investment aims to enhance the company's product offerings with intelligent support, optimizing the use of medical equipment and meeting the demand for efficient and precise healthcare [2]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1]. Core Insights - The global new drug business development (BD) remains robust, with approximately 31% of innovative drug candidates introduced by multinational pharmaceutical companies in 2024 coming from China. In the first two months of 2025, there have already been 16 Chinese innovative drug BD projects, expanding from oncology to autoimmune diseases [3]. - The weight loss market is seeing multiple BD agreements, with significant sales figures reported by Novo Nordisk and Eli Lilly. Novo Nordisk's core products generated sales of approximately $27.94 billion in 2024, while Eli Lilly's Mounjaro saw a 124% year-on-year increase in sales to $11.54 billion [5]. - CAR-T cell therapy continues to progress, with global sales expected to reach approximately $4.53 billion in 2024. Chinese companies are also participating in the global CAR-T sales, indicating their technological capabilities [6]. - The gene sequencing industry is accelerating its domestic production capabilities following export restrictions on Illumina's sequencing instruments. Domestic alternatives are rapidly emerging, with several companies receiving regulatory approvals for their sequencing devices [7]. - AI in healthcare is advancing, with various AI models being developed for specific medical fields. Collaborations between tech companies and healthcare providers are enhancing the integration of AI into traditional medical practices [9]. Summary by Sections Industry Trends - The pharmaceutical industry outperformed the CSI 300 index by 0.18 percentage points in the past week, with a weekly increase of 1.77% [23]. - Over the past month, the pharmaceutical sector also outperformed the CSI 300 index by 0.22 percentage points, with a monthly increase of 1.94% [27]. Subsector Performance - The pharmaceutical commercial sector saw the highest weekly increase of 6.44%, while the medical device sector had the lowest at 1.09% [30]. - Over the past year, the chemical pharmaceutical sector had the highest increase of 6.49%, while the biological products sector experienced a decline of 17.62% [37]. Company Recommendations - The report recommends focusing on companies involved in weight loss and NASH, such as Zhongsheng Pharmaceutical, and highlights the potential of companies like Geli Pharmaceutical and Lianbang Pharmaceutical [12]. - Companies engaged in CAR-T technology, such as Kexin Pharmaceutical, are also recommended as they approach market entry [12]. - The report emphasizes the importance of AI integration in medical devices, recommending companies like Anbiping and RunDa Medical for their competitive advantages [12]. Recent Developments - The report notes significant recent financing and regulatory approvals for various companies, indicating a dynamic and evolving market landscape [54][55].

将投中网设为"星标⭐"，第一时间收获最新推送 投中信息第五年发布"投中榜·锐公司100榜单"，关注包括人工智能、机器人、低空经济、商业航天、 医疗健康等诸多科技创新赛道。 "2024投中榜·锐公司100"榜单，以上述领域的成长性企业在资本市 场的活跃度为基础，选出融资活跃度高、成长性强的企业，并以"锐"冠名之。锐即芒，从金而兑声， 自是锋芒毕露，生就勇往直前，于大千世界，森罗万象中。执着于理想，纯粹于当下，投中信息以资 本的视角观察科技创新的发展历程，让未来的轨迹更加触手可及。 本次榜单评选投中研究院从企业外部关注度、产业协同性以及产业影响力三大维度，综合进行报名征 集、问卷调研、市场挖掘、行业专家走访及数据分析等流程，综合评选出100家年度最具创新力和成 长力的创新科技企业。 根据问卷调研和CVSource投中数据统计，在本次入榜企业中， 约75%处于D轮前的融资阶段，表明 投资机构对于具有高增长潜力的创业企业给予了充分信任和支持。 值得注意的是， 部分企业甚至在 不到一年时间便完成了多轮融资 ，显示出资本市场的高度认可，反映出投资机构对于优质资产追逐 的热情，并为中国科技产业注入了源源不断的活力。北京、上 ...

Core Viewpoint - The article discusses the rapid development and commercialization of AI in the healthcare sector, particularly focusing on the impact of the DeepSeek model, which is reshaping the landscape of medical AI applications and investment opportunities [2][4][5]. Group 1: AI in Healthcare - The integration of AI in healthcare is not new, but the emergence of DeepSeek has reignited interest and investment in the sector, with over 30 companies in China embedding this technology into drug development, clinical decision-making, and chronic disease management [2][3]. - The stock performance of medical AI companies has been strong in various markets, with many stocks nearly doubling in value within a month [3][4]. - The long-term growth logic of the healthcare industry is becoming clearer, with predictions that AI will present significant investment opportunities in 2025 [4]. Group 2: DeepSeek's Impact - DeepSeek's low-cost and high-efficiency model significantly empowers the development of medical AI, reducing the costs associated with model training and inference by over 90% [9]. - The open-source strategy of DeepSeek allows healthcare companies to customize and optimize AI models for specific medical applications, enhancing the commercial viability of AI in healthcare [10][12]. - The ability to deploy DeepSeek locally addresses data privacy concerns, as sensitive medical data does not need to be uploaded to the cloud [12][13]. Group 3: Long-term Value and Applications - The core value of medical AI lies in its potential to provide accessible, precise, and sustainable healthcare services, especially in the context of an aging population and rising chronic diseases [15]. - AI can enhance the efficiency of various medical processes, including drug development, diagnostics, and patient management, thereby improving overall healthcare quality [16]. - Predictive AI is emerging as a significant area of focus, with the potential to assess future health risks and promote proactive healthcare measures [17]. Group 4: Data Challenges - The success of medical AI relies heavily on high-quality data, yet challenges remain regarding compliance, standardization, and data quality in the healthcare sector [18][19]. - The fragmentation of medical data across different institutions complicates the integration into comprehensive databases, posing significant technical and regulatory challenges [18]. Group 5: Investment Opportunities - The current market offers opportunities to identify companies with strong data and model capabilities, as well as those with established B2B customer bases in electronic medical records and clinical decision support [27]. - The year 2025 is anticipated to be a pivotal moment for the commercialization of medical AI, as the industry seeks transformative breakthroughs [27].

Group 1 - The core viewpoint of the article emphasizes the strong recent stock performance and financial results of Tempus AI, highlighting the synergistic effect of its business model combining genomics, data services, and AI applications [2][6][9] - Tempus AI has established a comprehensive platform that facilitates real-time access to medical data, enabling precision medicine and breaking down data silos among doctors, diagnostic companies, and pharmaceutical firms [3][4][38] - The company has three main product lines: genomics, data services, and AI applications, with a focus on oncology and expanding into other disease areas [3][11][14] Group 2 - Tempus AI's revenue has shown impressive growth, with annual revenue increasing from $1.88 billion in 2020 to $6.93 billion in 2024, reflecting a CAGR of 39% [11][28] - The genomics segment is the largest contributor to revenue, with a significant increase in the number of tumor NGS tests and average reimbursement amounts, driving demand and revenue growth [21][20] - Data services have also seen substantial growth, with revenue rising from $0.36 billion in 2020 to $2.42 billion in 2024, supported by partnerships with major pharmaceutical companies [28][25] Group 3 - The AI applications segment is still in its early commercialization stage but holds significant future market potential, with products integrated into electronic health records to enhance clinical trial matching and patient care [31][39] - The company leverages a vast and diverse data source, having established partnerships with approximately 3,000 medical institutions, creating one of the largest proprietary databases in oncology [38][39] - Tempus AI's business model creates a flywheel effect, where increased patient testing leads to more data, enhancing data services and AI applications, thus driving further growth [33][34] Group 4 - The article discusses why there is currently no equivalent of Tempus AI in the domestic market, citing challenges such as fragmented data systems and slower adoption of innovative testing methods into insurance reimbursement [42][48] - The potential for breakthroughs in data sharing and integration is highlighted, with ongoing efforts to improve the data flow mechanisms within the domestic healthcare system [47][48] Group 5 - Investment insights for the A-share market are provided, suggesting a focus on companies that can leverage genomic data and AI technologies, with specific recommendations for firms like BGI Genomics and KingMed Diagnostics [52][53]

2025 年 2 月 17 日 星期一 ➢ 每日大市点评 中国 AI 投资概念火热，叠加美国总统特朗普的对等关税延迟等因素，共同刺激港股继续向上，上周四美国最新 PPI 部分 分项数据指向 1 月的核心 PCE 增速有望继续下行，带动美元指数破位向下，同期非美市场货币上升，资金流利好港股表 现。上周恒生指数全周大涨 7.0%，收报 22,620 点，创去年 10 月 7 日以来收市新高。恒生科指全周上升 7.3%，收报 5,526 点，创自 2022 年 2 月中旬以来收市新高。上周大市日均成交金额按周大增 64.8%至 2,980 多亿港元。从市场内部升市结 构看来，AI+是本轮港股的主线，包括信息科技、医疗保健、电讯、工业等综合行业分类指数表现突出。 ➢ 近期研报摘要分享 【中泰国际】中国房地产周报 (2025.02.03 - 02.09)：假期效应影响整体成交，但一线城市展现活力 当前内部处于政策及经济数据的空窗期，AI 提高中国企业营运效率成部分外资及对冲基金增配的逻辑，而外部特朗普采 取"攘外必先安内"的政策，对华压力边际舒缓，都给予港股向上的窗口。上周港股成交持续增加，人民币转强，中国 10 年期 ...

一周IPO动态，覆盖港股、美股、A股。 本文为IPO早知道原创 作者｜C叔 微信公众号｜ipozaozhidao 毛戈平 港股｜挂牌上市 据IPO早知道消息，毛戈平化妆品股份有限公司（以下简称"毛戈平"）于2024年12月10日正式 以"1318"为股票代码在港交所主板挂牌上市，成为"港股国货高端美妆第一股"。 毛戈平在本次IPO中总计发行70,588,200股H股。其中，香港公开发售部分获919.18倍认购，国际 发售部分亦获30.34倍认购，累计认购总额超华润饮料时的认购规模、成为今年港股「冻资王」。 同时，毛戈平在本次IPO发行中共引入6名基石投资者，累计认购1亿美元。其中，CPE认购3500万 美元，正心谷资本认购2000万美元，ACCF Capital（由原L Catterton Asia合伙人王俊创办）认购 1500万美元，常春藤基金、Brilliant Partners Fund LP以及大湾区共同家园投资基金分别认购1000 万美元。 成立于2000年的毛戈平现旗下拥有两大品牌——旗舰品牌MAOGEPING于2000年推出，根据弗若 斯特沙利文的资料，其为中国第一个高端美妆品牌且在所有国货品牌 ...